G2gbio

At a glance

G2gbio filed 66 disclosures in the last 12 months, including 23 insider, 3 5% holder and 3 issuance. The most recent key filing was on Aug 21: A major holder's stake fell from 25.34% to 22.90% (related-party change).

Revenue for 2025 was ₩423.1M, down 45% on 2024. It made an operating loss of ₩12.2B. Debt was 16% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩2B and operating loss of ₩6B.

The 2025 annual report lists 48 employees with an average tenure of 3.4 years and average pay of ₩125.4M. Its 6 directors and auditors were paid ₩161M each on average. It paid no cash dividend for 2025. 이희용 and related parties held 16.70% at year end.

Of 5 recent 5%+ holder reports, 2 raised and 3 cut a stake; the largest stake reported was 27.99% on Jun 5.

From the 2025 annual report

Staff: 48 (28 men, 20 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩6B. Directors and auditors: 6, paid ₩965M in total.

No cash dividend was paid for 2025.

Largest shareholder

이희용 holds 11.00%; with 17 related parties the group holds 16.70% of common shares at year end (from 27.50% at the start of the year).

Auditor: 신우회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports